Sequential tendon ruptures in ochronosis: case report

E. G. Mohan Kumar, G. M. Yathisha Kumar


Alkaptonuria is a rare autosomal recessive disorder characterised by the absence of homogentisic acid oxidase, due to deficiency of an enzyme that degrades HGA in the tyrosine degradation pathway. Homogentisic acid (HGA) and its metabolites accumulate in the connective tissues leading to dark pigmentation of connective tissue in patients with alkaptonuria. HGA deposits in connective tissue causes weakness of the tendon and subsequent rupture, especially the large tendons in the body. Only few cases are reported in the literature with multiple tendon rupture but many case reports are available with isolated rupture of tendons. We report on a patient with sequential tendon ruptures in a patient. The case is reported for its rarity.


Ochronosis, Multiple tendon ruptures, Medical prophylaxis in ochronosis

Full Text:



MV Ngcelwane, M Mandaba, TQ Bam. Multiple tendon ruptures in ochronosis: case report and review of prophylactic therapy: SA Orthopaedic J Autumn. 2013;12.

Babanagare SV, Deshmukh SD, Khadilkar MS, Patil AA. Ochronosis: a report of three cases and review of the literature. Indian J Pathol Microbiol. 2011;54(3):626-8.

Khaled A, Kerkeni N, Hawilo A, Fazaa B, Kamoun MR. Endogenous ochronosis: case report and a systematic review of the literature. Int J Dermatol. 2011;50(3):262-7.

Prakash V, Boston DA, Packer GJ, Raza SA. Rupture of a black tendon: ochronotic tendo-Achilles rupture. The Foot. 2003;13(1):49-50.

Mc Colum DE, Odom GL. Alkaptonuria, ochronosis and low back pain: a case report. J Bone Joint Surg (Am). 1965;47-A:1389-92.

Carrier DA, Harris CM. Bilateral hip and bilateral knee arthroplasties in a patient with ochronotic arthropathy. Orthop Rev. 1990;19(11):1005-9.

Laskar FH, Sargison KD. Ochronotic arthropathy. A review with four case reports. J Bone Joint Surg Br. 1970;52(4):653-66.

Morava E, Kosztalanyi G, Engelke UFH, Wevers RA. Reversal of clinical symptoms and radiographic abnormalities with protein restriction and ascorbic acid in alkaptonuria. Ann Clin Biochem, 2003;40(Pt 1):108-11.

Suwannarat P, O’Brien K, Perry MB, Sebring N, Bernardini I, Kaiser- Kupfer MI, Rubin BI, Tsilou E, Gerber LH, Gahl WA. Use of nitisinone in patients with alkaptonuria. Metabolism. 2005;54(6):719-28.

Introne WJ, Perry MB, Troendle J, Tsilou E, Kayser MA, Suwannarat P, et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab, 2011;103(4):307-14.